C9 and age-related macular degeneration: To assess the consequences of the complement C9 rare genetic variant P167S in AMD, plasma C9 levels were initially measured in the US cohort, revealing a significantly lower median plasma C9 level associated with the P167S variant (14.7 vs. 23.5 μg/ml, P < 0.0001).